Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 16/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 16/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301672 | 0.88 | ADORA2A (0.39) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2685086 | 0.88 | ADORA2A (0.39) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2301677 | 0.88 | ADORA2A (0.39) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2683561 | 0.87 | MLYCD (0.39) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2685065 | 0.87 | MLYCD (0.39) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2683559 | 0.87 | MLYCD (0.39) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2685824 | 0.86 | CNR1 (0.40) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2685844 | 0.86 | CNR1 (0.40) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2685828 | 0.86 | CNR1 (0.40) | TAS1R3TAS1R1ADORA2AHDAC3HDAC1 | |
| SCHEMBL2308055 | 0.82 | ADORA2A (0.49) | ADORA2AHDAC6CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350073-B1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-12 | — | — | EP | claimed |
| EP-2350073-A1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010034799-A1 | 3H-IMIDAZ0 [4, 5-B] PYRIDINE- 6 -CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| EP-2350073-B1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2010034799-A1 | 3H-IMIDAZ0 [4, 5-B] PYRIDINE- 6 -CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | TAS1R3 1707/4885TAS1R1 2569/4885ADORA2A 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.